BP
DNLI icon

Ballentine Partners’s Denali Therapeutics DNLI Stock Holding History

Ballentine Partners’s Portfolio DNLI Stock Details DNLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-25,000
Closed -$544K – 355
2018
Q3 		$544K Buy
+25,000
New +$414K 0.03% 187

Other funds holding DNLI

CM
Crestline Management Fort Worth, Texas $53.5M AUM 80.67% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.54B AUM 86.39% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $34.9B AUM 72.7% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $139B AUM 29.06% 1-Year Est. Return

Ballentine Partners's DNLI Position: Q4 2018 in Review

Ballentine Partners sold out of Denali Therapeutics (DNLI) in Q4 2018, closing a stake of 25,000 shares — an estimated $544K sold.

Ballentine Partners first reported a position in DNLI in Q3 2018 and held it in 1 quarter. The position peaked at $544K in Q3 2018. 90 funds tracked by Wall St. Rank hold DNLI as of Q4 2018.

  • Ballentine Partners reported no remaining Denali Therapeutics position as of Q4 2018 after selling out during the quarter.
  • Ballentine Partners sold 25,000 Denali Therapeutics shares in Q4 2018, an estimated $544K.
  • Ballentine Partners first reported a position in Denali Therapeutics in Q3 2018 and held it in 1 quarter.
  • Ballentine Partners's Denali Therapeutics position peaked at $544K in Q3 2018.
  • 90 funds tracked by Wall St. Rank held Denali Therapeutics as of Q4 2018.

Based on Ballentine Partners's 13F filing for Q4 2018, filed 4 Feb 2019.